https://www.selleckchem.com/products/lf3.html
27; 95% CI 0.06 to 1.12; p = 0.07; heterogeneity Q 0.00001; I2 = 90%). It significantly lowered the Child-Turcotte-Pugh (MD=-0.97, 95% CI -1.48 to -0.45; p = 0.0003; heterogeneity Q = 0.25; I2 = 28%). No serious adverse events were observed. Granulocyte-colony stimulating factor resulted in significantly improved 12-month survival and reduced Child-Turcotte-Pugh score with relative safety. Establishment of guidelines and protocols in future clinical trials will promote granulocyte-colony stimulating factor as an effective and safe ther
Like
Comment
Share
